GMAB Investors, You Need to Know These Facts Today.

By Emilio Sanchez • Monday, May 26 09:56 • Permanent Link

Genmab A/S ADS logged a -1.0% change during today's morning session, and is now trading at a price of $20.81 per share. The S&P 500 index moved -1.0%. GMAB's trading volume is 1,247,688 compared to the stock's average volume of 1,539,681.

Genmab A/S ADS trades -29.01% away from its average analyst target price of $29.31 per share. The 8 analysts following the stock have set target prices ranging from $20.0 to $45.0, and on average have given Genmab A/S ADS a rating of buy.

If you are considering an investment in GMAB, you'll want to know the following:

Genmab A/S ADS's current price is -97.6% below its Graham number of $881.38, which implies the stock has a margin of safety
Genmab A/S ADS has moved -25.7% over the last year, and the S&P 500 logged a change of 9.4%
Based on its trailing earnings per share of 1.7, Genmab A/S ADS has a trailing 12 month Price to Earnings (P/E) ratio of 12.2 while the S&P 500 average is 29.3
GMAB has a forward P/E ratio of 14.9 based on its forward 12 month price to earnings (EPS) of $1.4 per share
Its Price to Book (P/B) ratio is 0.25 compared to its sector average of 3.19
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Based in Copenhagen, the company has 2,638 full time employees and a market cap of $12.84 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.